Revolution Medicines, Inc. (RVMD)
| Market Cap | 1.25B |
| Revenue (ttm) | 26.84M |
| Net Income (ttm) | -207.56M |
| Shares Out | 74.25M |
| EPS (ttm) | -2.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 580,594 |
| Open | 15.88 |
| Previous Close | 15.89 |
| Day's Range | 15.17 - 16.92 |
| 52-Week Range | 14.08 - 35.07 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | 31.82 (+88.3%) |
| Earnings Date | May 9, 2022 |
About RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the...
Financial Performance
In 2021, RVMD's revenue was $29.39 million, a decrease of -31.62% compared to the previous year's $42.98 million. Losses were -$187.09 million, 73.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is 31.82, which is an increase of 88.28% from the latest price.
News
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Misses Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 4.88% and 24.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic
7 Stocks That Insiders Are Buying Now. Should You?
Here are seven stocks that have recently seen large amounts of insider purchases: Asana (NYSE:ASAN) Ford (NYSE:F) GameStop (NYSE:GME) Eastman Kodak (NYSE:KODK) Oric Pharmaceuticals (NASDAQ:ORIC) Revolut...
Insiders Buy More Than $19M Of 3 Stocks
Although US stocks closed sharply higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view ...
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annu...
Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as Presentations in “Chemistry to the Clinic” and “Challenging T...
Revolution Medicines to Participate in Cowen 42nd Annual Health Care Conference
REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today ...
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.23% and 15.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the s...
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2021 After Market Close on February...
Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Monday, February 28, 2022, at 4:30 p.m. Eastern Time
Revolution Medicines to Participate in Guggenheim Healthcare Talks 2022 Oncology Conference
REDWOOD CITY, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today a...
Revolution Medicines Reports Progress Across Pipeline of Targeted Therapeutics for RAS-Addicted Cancers in Presentati...
RAS(ON) Inhibitor Pipeline Expands with Advancement of Two New Drug Candidates; Development-Stage Portfolio Covers RAS Drivers of Majority of RAS-Addicted Cancers
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
REDWOOD CITY, Calif., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier ta...
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -16.13% and -88.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for th...
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier ta...
Earnings Preview: Revolution Medicines, Inc. (RVMD) Q3 Earnings Expected to Decline
Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual Intern...
Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session Company Invited to Deliver Oral Presentation in “Drugging Difficult Targets” Plenary Session
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs Company's Scientific Leadership to Highlight Key Findings from Ongoing RAS(ON) Inhibitor Programs
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company focused on developing targeted drugs to inhibit frontier t...
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -9.09% and -19.54%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines: Q2 Earnings Insights
Shares of Revolution Medicines (NASDAQ:RVMD) fell 8.0% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 30.43% year over year to ($0.60), whi...
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time
Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline
Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeti...
Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemica...